XinYi Shen1, MingYi Liu2, Yu Cheng3, Cui Jia4, XinYue Pan5, QingYun Gou6, XinLian Liu7, Hui Cao8, LuShun Zhang9. 1. Department of Clinical Medicine, Chengdu Medical College, Chengdu 610500, China. Electronic address: a976443005@qq.com. 2. Department of Clinical Medicine, Chengdu Medical College, Chengdu 610500, China. Electronic address: 786699618@qq.com. 3. Department of Clinical Medicine, Chengdu Medical College, Chengdu 610500, China. Electronic address: 609623127@qq.com. 4. Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu 610500, China. Electronic address: 183431605@qq.com. 5. Department of Clinical Medicine, Chengdu Medical College, Chengdu 610500, China. Electronic address: 353212334@qq.com. 6. Department of Clinical Medicine, Chengdu Medical College, Chengdu 610500, China. Electronic address: gqy2298462@126.com. 7. Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu 610500, China. Electronic address: 504080342@qq.com. 8. Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu 610500, China. Electronic address: xinxiang1987106@163.com. 9. Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu 610500, China; Development and Regeneration Key Laboratory of Sichuan Province, Department of Neurobiology, Chengdu Medical College, Chengdu 610500, China. Electronic address: zhangls2012@163.com.
Abstract
BACKGROUND: Every year, more than fifteen million people worldwide experience a stroke, nearly 30% of stroke survivors are likely to experience post-stroke depression (PSD). Repetitive transcranial magnetic stimulation (rTMS) is one of the emerging techniques which assist in targeting rehabilitation after stroke. Although deterioration of PSD greatly affects the recovery and quality of life of stroke sufferers, the effect of rTMS therapy has not been systematically studied. OBJECTIVE: A systematic review and meta-analysis was conducted to determine the effect of rTMS on PSD. METHODS: We carried out a systematic review and meta-analysis of randomized controlled trials (RCTs) of rTMS for the treatment of PSD. Primary outcome was severity of depression measured by the Hamilton Depression Rating Scale (HAMD). Secondary outcomes were response rates, remission rates, stroke severity and ability to perform daily activities. RESULTS: 22 RCTs studies (n=1764 patients) were included. The results demonstrated that rTMS was beneficial on PSD using three scales: HAMD (MD=-6.09, 95% CI: -7.74, -4.45, P<0.001); response rates (OR=3.46, 95% CI: 2.52, 4.76, P<0.00001); remission rates (OR 0.99, 95% CI: 0.56, 1.75, P<0.00001); National Institutes of Health Stroke Scale (NIHSS) (MD=-2.74, 95% CI: -3.33, -2.15, P<0.001); Activities of daily living (ADL) (SMD=-1.20, 95% CI: 0.68, 1.72, P<0.001); Montgomery-Asberg Depression Scale (MARDE) (MD=-6.21; 95% CI: -9.34, -3.08; P=0.0001); CONCLUSION: In present meta-analysis, the positive findings suggest rTMS has beneficial effects on PSD. However, those findings should be treated with caution because of heterogeneity and potential biases.
BACKGROUND: Every year, more than fifteen million people worldwide experience a stroke, nearly 30% of stroke survivors are likely to experience post-stroke depression (PSD). Repetitive transcranial magnetic stimulation (rTMS) is one of the emerging techniques which assist in targeting rehabilitation after stroke. Although deterioration of PSD greatly affects the recovery and quality of life of stroke sufferers, the effect of rTMS therapy has not been systematically studied. OBJECTIVE: A systematic review and meta-analysis was conducted to determine the effect of rTMS on PSD. METHODS: We carried out a systematic review and meta-analysis of randomized controlled trials (RCTs) of rTMS for the treatment of PSD. Primary outcome was severity of depression measured by the Hamilton Depression Rating Scale (HAMD). Secondary outcomes were response rates, remission rates, stroke severity and ability to perform daily activities. RESULTS: 22 RCTs studies (n=1764 patients) were included. The results demonstrated that rTMS was beneficial on PSD using three scales: HAMD (MD=-6.09, 95% CI: -7.74, -4.45, P<0.001); response rates (OR=3.46, 95% CI: 2.52, 4.76, P<0.00001); remission rates (OR 0.99, 95% CI: 0.56, 1.75, P<0.00001); National Institutes of Health Stroke Scale (NIHSS) (MD=-2.74, 95% CI: -3.33, -2.15, P<0.001); Activities of daily living (ADL) (SMD=-1.20, 95% CI: 0.68, 1.72, P<0.001); Montgomery-Asberg Depression Scale (MARDE) (MD=-6.21; 95% CI: -9.34, -3.08; P=0.0001); CONCLUSION: In present meta-analysis, the positive findings suggest rTMS has beneficial effects on PSD. However, those findings should be treated with caution because of heterogeneity and potential biases.
Authors: Shan H Siddiqi; Nicholas T Trapp; Carl D Hacker; Timothy O Laumann; Sridhar Kandala; Xin Hong; Ludwig Trillo; Pashtun Shahim; Eric C Leuthardt; Alexandre R Carter; David L Brody Journal: J Neurotrauma Date: 2019-01-07 Impact factor: 5.269